klˈɪnɪkəl tɹˈaɪəlz ʌv sˈɑːɹɡɹɐmˌoʊstɪm wɜːɹ ɪnˈɪʃɪˌeɪɾᵻd ɪn nˈaɪntiːnhˈʌndɹɪd ˈeɪɾi sˈɛvən; ɪn ðæt sˈeɪm jˈɪɹ ɪt wʌz ɐdmˈɪnɪstɚd tə sˈɪks pˈiːpəl æz pˈɑːɹt əvə kəmpˈæʃənətjˈuːs pɹˈoʊɾəkˌɑːl fɚðə vˈɪktɪmz ʌv sˈiːziəm ˌɪɹeɪdɪˈeɪʃən fɹʌmðə ɡˈɔɪənˌiə ˈæksɪdənt.
Clinical trials of sargramostim were initiated in 1987; in that same year it was administered to six people as part of a compassionate-use protocol for the victims of cesium irradiation from the Goiânia accident.